[vc_row][vc_column][vc_column_text]
Despite significant advances in screening and treatment of cervical dysplasias
strongly associated with high-risk human papilloma virus infection
cervical cancer is the fifth most common cancer in European women. Cervical cancer
incidence and mortality due to cervical cancer major differences are available between regions.
European Society of Gynecological Oncology (ESGO), European Radiotherapy and Oncology
Society (ESTRO) and European Society of Pathology (ESP) for cervical cancer patients
staging, fertility sparing surgery, management (stage T1a, T1b1 / T2a1, simple
hidden hysterectomy clinically diagnosed cervical cancer, locally advanced
cervical cancer, primary distant metastatic disease, cervical cancer in pregnancy
and recurrent disease) and follow-up.
.Prognostic factors
In accordance with the following major tumor-related prognostic factors
It is recommended to register:
TNM and FIGO stage; Maximum tumor size, extracervical tumor •
detailed description of the extension and nodal involvement (number, size,
location)
Pathological tumor type •
Depth of cervical stromal invasion and non-affected cervical stroma •
Minimum thickness •
Presence or absence of lymphovascular area involvement (LVSI)
Presence or absence of distant metastasis •
Local clinical and radiological diagnostic evaluation
Pelvic examination and biopsy +/- colposcopy mandatory diagnosis of cervical cancer components.
Pelvic magnetic resonance (MRI) guides treatment options and mandatory onset to indicate pelvic tumor extension and evaluation.
Endovaginal / transrectal ultrasound by an experienced sonographer is also an option.
Cystoscopy or rectoscopy, MRI or ultrasound of bladder or rectum is up to tumor extension. And if a suspicious lesion has been shown, biopsy can be performed
[/vc_column_text][/vc_column][/vc_row]